HLOSF.US Healios K.K

Healthcare Biotechnology USA Stocks
1.80 USD
Close of Nov 15, 2026
1.80 3.40
Market cap
USD 243M
P/E
180.0x
P/B
5.10x
ROE
-91.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HLOSF.US undervalued?

Graham number

The Graham number of Healios K.K cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Healios K.K fundamental analysis

No fundamental analysis for Healios K.K yet.

Healios K.K stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Healios K.K

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of…

Full company profile